You are currently browsing the archives for 3 May 2018.
Displaying 1 entry.

An investigational therapeutic vaccine getting developed to treat herpes simplex virus-2.

Antigenics announces excellent results of AG-707 genital herpes vaccine Antigenics announced positive results with AG-707, an investigational therapeutic vaccine getting developed to treat herpes simplex virus-2 , the virus that triggers genital herpes, in infected individuals nolvadex review http://www.nolvadex-d.net . Developed by Antigenics, the vaccine triggers a cellular immune response, stimulating both CD4+ and CD8+ T cells. Latest data suggest both of these arms of immunity are needed for successful treatment of genital herpes.D., research professor and investigator of Medication, Laboratory Medication and Global Health Medicine, University of Washington.